PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

PETACH TIKVA,Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26^th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024.

Barclays 26^th Annual Global Healthcare Conference Fireside Chat

The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid around the conference should contact their Barclays representative.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts:
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
[email protected]

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
[email protected]

You May Also Be Interested In

• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
• Best Crypto to Buy Now Is Not ETH or SOL and Pepeto Proves Why Before
• HTX Research Examines U.S. AI Equities: Technology Remains Early, While Capital Expenditure and Valuations Have Entered the Late Cycle